Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer (POLAR-A)
A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in the Adjuvant Treatment of Patients With Stage III or High-risk Stage II Colorectal Cancer
Sponsor: Egetis Therapeutics
Terminated
On 01 March 2020, the Sponsor decided to place recruitment and dosing of patients on hold following interactions with the French regulatory authority, ANSM and the US clinical hold of another study (POLAR-M).
Other terminated trials from Egetis Therapeutics
More terminations from Egetis Therapeutics
Other Chemotherapy-induced Peripheral Neuropathy trials with similar outcome
Browse all Chemotherapy-induced Peripheral Neuropathy trials
This PHASE3 trial investigates Chemotherapy-induced Peripheral Neuropathy and Colorectal Cancer and is currently terminated or withdrawn. Egetis Therapeutics leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Oct 2021 — Feb 2022 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Aug 2019 — Dec 2019 [monthly]
Recruiting PHASE3
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Egetis Therapeutics
- Solasia Pharma K.K.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Anyang-si, South Korea , Augsburg, Germany , Barcelona, Spain , Benešov, Czechia , Bonheiden, Belgium , Brest, France , Brussels, Belgium , Busan, South Korea , Chelmsford, United Kingdom and 44 more locations